Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Antiretroviral therapy improves renal function among HIV-infected Ugandans
Kidney International, Volume 74, No. 7, Year 2008
Notification
URL copied to clipboard!
Description
Renal dysfunction is a severe complication of advanced HIV disease. We evaluated the impact of highly active antiretroviral therapy (HAART) on renal function among HIV-infected Ugandans in the Home-Based AIDS Care clinical trial. The patients presented with symptomatic HIV disease or CD4 cell count ≤250 cells/mm3 and creatinine clearances above 25 ml/min determined by the Cockcroft-Gault equation. Of the 508 patients at baseline, 8% had a serum creatinine over 133 μmol/l and about 20% had reduced renal function evidenced by a creatinine clearance between 25 and 50 ml/min. After 2 years of HAART, the median serum creatinine was significantly decreased by 16% while the median creatinine clearance significantly increased 21%. The median creatinine clearance of patients with renal dysfunction at baseline, increased by 53% during 2 years of treatment. In multivariable analysis, a baseline creatinine above 133 μmol/l, a weight gain of more than 5 kg over the 2 years, female gender and a WHO stage 4 classification were all associated with greater improvements in creatinine clearance on HAART. Our study shows that renal dysfunction was common with advanced HIV disease in Uganda but this improved following 2 years of HAART. © 2008 International Society of Nephrology.
Authors & Co-Authors
Peters, Philip James
United States, Atlanta
National Center for Hiv, Viral Hepatitis, Std, and tb Prevention
United States, Atlanta
Centers for Disease Control and Prevention
Moore, David M.
Uganda, Entebbe
Uganda Virus Research Institute
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Canada, Vancouver
The University of British Columbia
Mermin, Jonathan H.
Uganda, Entebbe
Uganda Virus Research Institute
Brooks, John T.
United States, Atlanta
National Center for Hiv, Viral Hepatitis, Std, and tb Prevention
Downing, Robert G.
Uganda, Entebbe
Uganda Virus Research Institute
Were, Willy A.
Uganda, Entebbe
Uganda Virus Research Institute
Kigozi, Aminah N.
Uganda, Entebbe
Uganda Virus Research Institute
Buchacz, Kate A.
United States, Atlanta
National Center for Hiv, Viral Hepatitis, Std, and tb Prevention
Weidle, Paul J.
United States, Atlanta
National Center for Hiv, Viral Hepatitis, Std, and tb Prevention
Statistics
Citations: 118
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1038/ki.2008.305
ISSN:
00852538
e-ISSN:
15231755
Research Areas
Infectious Diseases
Study Locations
Uganda
Participants Gender
Female